inclusion criteria: * written informed consent * healthy male and female adults aged 18-55 years * no clinically significant health problems as determined during medical history and physical examination at screening visit * body mass index 18.5 - 30.0 kg/m2 and weight \> 50 kg at screening * adults male or non-pregnant, non-lactating female with negative pregnancy test * males and females who agree to comply with the applicable contraceptive requirements of the protocol inclusion criteria for the subjects before the 3rd/4th (=booster) vaccination: 1. ability to understand the subject information and to personally name, sign and date the in-formed consent to participate in the study. 2. provided written informed consent. 3. continues to be in stable health condition as determined during medical history and physi-cal examination on vaccination visits. 4. non-pregnant, non-lactating female with a negative pregnancy test at screening and on dosing days (prior to vaccination). 5. be willing to refrain from blood donation during the course of the study. 6. the subject is co-operative and available for the entire study. 7. need to have participated in previous part of the mva-sars-2-s vaccine study (eudra-ct no: 2020-002998-10)

inclusion criteria: * written informed consent * healthy male and female adults aged 18-55 years * no clinically significant health problems as determined during medical history and physical examination at screening visit * body mass index 18.5 - 30.0 kg/m2 and weight \> 50 kg at screening * adults male or non-pregnant, non-lactating female with negative pregnancy test * males and females who agree to comply with the applicable contraceptive requirements of the protocol inclusion criteria for the subjects before the 3rd/4th (=booster) vaccination: 1. ability to understand the subject information and to personally name, sign and date the in-formed consent to participate in the study. 2. provided written informed consent. 3. continues to be in stable health condition as determined during medical history and physi-cal examination on vaccination visits. 4. non-pregnant, non-lactating female with a negative pregnancy test at screening and on dosing days (prior to vaccination). 5. be willing to refrain from blood donation during the course of the study. 6. the subject is co-operative and available for the entire study. 7. need to have participated in previous part of the mva-sars-2-s vaccine study (eudra-ct no: 2020-002998-10)

inclusion criteria: written informed consent healthy male and female adults aged 18-55 years no clinically significant health problems as determined during medical history and physical examination at screening visit body mass index 18.5 - 30.0 kg/m2 and weight > 50 kg at screening adults male or non-pregnant, non-lactating female with negative pregnancy test males and females who agree to comply with the applicable contraceptive requirements of the protocol inclusion criteria for the subjects before the 3rd/4th (=booster) vaccination: ability to understand the subject information and to personally name, sign and date the in-formed consent to participate in the study. provided written informed consent. continues to be in stable health condition as determined during medical history and physi-cal examination on vaccination visits. non-pregnant, non-lactating female with a negative pregnancy test at screening and on dosing days (prior to vaccination). be willing to refrain from blood donation during the course of the study. the subject is co-operative and available for the entire study. need to have participated in previous part of the mva-sars-2-s vaccine study (eudra-ct no: 2020-002998-10)

inclusion criteria: written informed consent healthy male and female adults aged 18-55 years no clinically significant health problems as determined during medical history and physical examination at screening visit body mass index 18.5 - 30.0 kg/m2 and weight > 50 kg at screening adults male or non-pregnant, non-lactating female with negative pregnancy test males and females who agree to comply with the applicable contraceptive requirements of the protocol inclusion criteria for the subjects before the 3rd/4th (=booster) vaccination: ability to understand the subject information and to personally name, sign and date the in-formed consent to participate in the study. provided written informed consent. continues to be in stable health condition as determined during medical history and physi-cal examination on vaccination visits. non-pregnant, non-lactating female with a negative pregnancy test at screening and on dosing days (prior to vaccination). be willing to refrain from blood donation during the course of the study. the subject is co-operative and available for the entire study. need to have participated in previous part of the mva-sars-2-s vaccine study (eudra-ct no: 2020-002998-10)

inclusion criteria: - written informed consent - healthy male and female adults aged 18-55 years - no clinically significant health problems as determined during medical history and physical examination at screening visit - body mass index 18.5 - 30.0 kg/m2 and weight > 50 kg at screening - adults male or non-pregnant, non-lactating female with negative pregnancy test - males and females who agree to comply with the applicable contraceptive requirements of the protocol inclusion criteria for the subjects before the 3rd/4th (=booster) vaccination: 1. ability to understand the subject information and to personally name, sign and date the in-formed consent to participate in the study. 2. provided written informed consent. 3. continues to be in stable health condition as determined during medical history and physi-cal examination on vaccination visits. 4. non-pregnant, non-lactating female with a negative pregnancy test at screening and on dosing days (prior to vaccination). 5. be willing to refrain from blood donation during the course of the study. 6. the subject is co-operative and available for the entire study. 7. need to have participated in previous part of the mva-sars-2-s vaccine study (eudra-ct no: 2020-002998-10)

inclusion criteria: - written informed consent - healthy male and female adults aged 18-55 years - no clinically significant health problems as determined during medical history and physical examination at screening visit - body mass index 18.5 - 30.0 kg/m2 and weight > 50 kg at screening - adults male or non-pregnant, non-lactating female with negative pregnancy test - males and females who agree to comply with the applicable contraceptive requirements of the protocol inclusion criteria for the subjects before the 3rd/4th (=booster) vaccination: 1. ability to understand the subject information and to personally name, sign and date the in-formed consent to participate in the study. 2. provided written informed consent. 3. continues to be in stable health condition as determined during medical history and physi-cal examination on vaccination visits. 4. non-pregnant, non-lactating female with a negative pregnancy test at screening and on dosing days (prior to vaccination). 5. be willing to refrain from blood donation during the course of the study. 6. the subject is co-operative and available for the entire study. 7. need to have participated in previous part of the mva-sars-2-s vaccine study (eudra-ct no: 2020-002998-10)

inclusion criteria: - written informed consent - healthy male and female adults aged 18-55 years - no clinically significant health problems as determined during medical history and physical examination at screening visit - body mass index 18.5 - 30.0 kg/m2 and weight > 50 kg at screening - adults male or non-pregnant, non-lactating female with negative pregnancy test - males and females who agree to comply with the applicable contraceptive requirements of the protocol

inclusion criteria: - written informed consent - healthy male and female adults aged 18-55 years - no clinically significant health problems as determined during medical history and physical examination at screening visit - body mass index 18.5 - 30.0 kg/m2 and weight > 50 kg at screening - adults male or non-pregnant, non-lactating female with negative pregnancy test - males and females who agree to comply with the applicable contraceptive requirements of the protocol